Phaseline

Companies › Edgewood Oncology

Edgewood Oncology: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BTX-A51–Phase 1Acute Myeloid Leukemia; Advanced Solid Tumor; LiposarcomaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06414434BTX-A51Phase 1LiposarcomaOncologyJan 2027
NCT04243785BTX-A51Phase 1Acute Myeloid LeukemiaOncologyMar 2027
NCT04872166BTX-A51Phase 1Advanced Solid TumorOncologyMay 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.